Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations

Posts by Mourabit Halima

Home » Archives for Mourabit Halima » Archives for Mourabit Halima
About Mourabit Halima
Bispecific CS1-BCMA CAR-T Cells Show Promise in Treating Relapsed or Refractory Multiple Myeloma: Phase I Clinical Trial Results

Bispecific CS1-BCMA CAR-T Cells Show Promise in Treating Relapsed or Refractory Multiple Myeloma: Phase I Clinical Trial Results

Posted by By Mourabit Halima 2024.03.17
Abstract: Multiple myeloma (MM) poses significant therapeutic challenges due to its heterogeneous nature. Bispecific chimeric antigen receptor T (CAR-T) cell therapy targeting CS1 and BCMA antigens offers a novel approach.…
Read More
Evaluating the Efficacy and Safety of Orelabrutinib-Based Regimens in Diffuse Large B-Cell Lymphoma: A Retrospective Analysis

Evaluating the Efficacy and Safety of Orelabrutinib-Based Regimens in Diffuse Large B-Cell Lymphoma: A Retrospective Analysis

Posted by By Mourabit Halima 2024.03.17
Abstract: Diffuse Large B-Cell Lymphoma (DLBCL) is a heterogeneous malignancy associated with significant morbidity and mortality. Orelabrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, has shown promise as a therapeutic agent…
Read More
Retrospective Analysis of bZIP Region Mutations in CEBPA Double-Mutated Acute Myeloid Leukemia: Implications for Prognosis and Treatment

Retrospective Analysis of bZIP Region Mutations in CEBPA Double-Mutated Acute Myeloid Leukemia: Implications for Prognosis and Treatment

Posted by By Mourabit Halima 2024.03.17
Editor's note: Acute Myeloid Leukemia (AML) characterized by CCAAT-enhancer binding protein alpha (CEBPA) double mutations (CEBPAdm) represents a distinct subtype with varying clinical outcomes. Recent attention has focused on the…
Read More
The Impact of CEBPA Mutations in Hematological Disorders: A Comprehensive Study

The Impact of CEBPA Mutations in Hematological Disorders: A Comprehensive Study

Posted by By Mourabit Halima 2024.03.17
Editor's note: Genetic mutations play a pivotal role in shaping the clinical presentation and prognosis of hematological disorders, with CEBPA mutations emerging as significant contributors to disease pathogenesis. This comprehensive…
Read More
Pediatric-Inspired Therapy Revolutionizes Treatment of Adult Acute Lymphoblastic Leukemia: Insights from a Groundbreaking Chinese Study

Pediatric-Inspired Therapy Revolutionizes Treatment of Adult Acute Lymphoblastic Leukemia: Insights from a Groundbreaking Chinese Study

Posted by By Mourabit Halima 2024.03.15
Introduction: Acute lymphoblastic leukemia (ALL) poses significant challenges in adult patient care, necessitating innovative treatment strategies. Addressing this need, a pioneering study conducted in China investigated the efficacy and safety…
Read More
the Role of the Pinch-Cxcl12-Mbl2 Pathway in Immune and Hematopoietic Homeostasis: Implications for Therapeutic Interventions

the Role of the Pinch-Cxcl12-Mbl2 Pathway in Immune and Hematopoietic Homeostasis: Implications for Therapeutic Interventions

Posted by By Mourabit Halima 2024.03.15
Editor's note: The interplay between bone marrow stromal cells (BMSCs) and immune as well as hematopoietic functions is a complex yet crucial aspect of maintaining overall health. In this study,…
Read More
Intensified Conditioning Regimens for High-Risk ALL Patients Undergoing Allo-HSCT: A Retrospective Analysis

Intensified Conditioning Regimens for High-Risk ALL Patients Undergoing Allo-HSCT: A Retrospective Analysis

Posted by By Mourabit Halima 2024.03.15
Editor's note: The prognosis of high-risk acute lymphoblastic leukemia (ALL) patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains variable, particularly concerning minimal residual disease (MRD) status. Professor Yu Hu…
Read More
Enhancing Early Infection Risk Prediction in Newly Diagnosed Multiple Myeloma: A Nomogram Prognostic Model Approach

Enhancing Early Infection Risk Prediction in Newly Diagnosed Multiple Myeloma: A Nomogram Prognostic Model Approach

Posted by By Mourabit Halima 2024.03.15
Editor's note: In patients with newly diagnosed multiple myeloma (NDMM), infections pose a significant threat to morbidity and mortality, particularly within the initial months post-diagnosis. Immunoparesis, characterized by reduced levels…
Read More
The Role of the Pinch-Cxcl12-Mbl2 Pathway in Immune and Hematopoietic Homeostasis: Implications for Therapeutic Interventions

The Role of the Pinch-Cxcl12-Mbl2 Pathway in Immune and Hematopoietic Homeostasis: Implications for Therapeutic Interventions

Posted by By Mourabit Halima 2024.03.15
Editor's note: The interplay between bone marrow stromal cells (BMSCs) and immune as well as hematopoietic functions is a complex yet crucial aspect of maintaining overall health. In this study,…
Read More
Neutrophil Plasticity in Cancer: A Gateway to Targeted Immunotherapy

Neutrophil Plasticity in Cancer: A Gateway to Targeted Immunotherapy

Posted by By Mourabit Halima 2024.03.15
Editor's note: Neutrophils, once viewed as uniform soldiers of the immune system, are now recognized for their remarkable plasticity within the tumor microenvironment. In a pioneering study led by Melissa…
Read More

Posts pagination

Previous page 1 … 20
Recent Posts
  • Published in The Lancet | First-in-Class Bispecific ADC Iza-bren Reshapes Clinical Treatment Decision-Making and Ushers in a New Era of Bispecific ADC Therapy for Breast Cancer
  • ESMO Investigator Insights | Professor Qingyuan Zhang: Robust Clinical Evidence Demonstrates the Strength of Iza-bren, Ushering in a New Era of Breast Cancer Treatment
  • ESMO Investigator Insights | Professor Shusen Wang: Reshaping the Breast Cancer Treatment Landscape—How Iza-bren Is Ushering in a New Era of Bispecific ADC Therapy
  • ESMO Investigator Insights | Professor Yehui Shi: Confronting Challenges and Breaking New Ground—How the World’s First Bispecific ADC, Iza-bren, Is Ushering in a New Era of Bispecific ADC Therapy for Breast Cancer
  • 2026 East China Breast Cancer Salon | Professor Yongmei Yin: A Decade of Academic Exchange and Mentorship—Advancing Evidence-Based Practice and Standardized Breast Cancer Care
Recent Comments
    Archives
    • November 2026
    • October 2026
    • September 2026
    • August 2026
    • July 2026
    • June 2026
    • May 2026
    • April 2026
    • March 2026
    • February 2026
    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2026 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Paris, France
    Scroll to Top